Document is current
Any future updates will be listed below
-
Authors
Compte, Emilio J.
Cattle, Chloe J.
Lavender, Jason M.
Brown, Tiffany A.
Murray, Stuart B.
Capriotti, Matthew R.
Flentje, Annesa
Lubensky, Micah E.
Obedin-Maliver, Juno
Lunn, Mitchell R.
Nagata, Jason M.
-
Funding
Funding for this research was provided by:
Office of Extramural Research, National Institutes of Health (K23 MH115184)
Office of Extramural Research, National Institutes of Health (K08HL159350)
National Institute on Drug Abuse (K23DA039800)
National Institute of Diabetes and Digestive and Kidney Diseases (K12DK111028)
Patient-Centered Outcomes Research Institute (PPRN‐1501‐26848)
American Heart Association (CDA34760281)
- License Information
-
More Information
Article History
Received: 26 April 2022
Accepted: 24 June 2022
First Online: 6 July 2022
Declarations
:
: The University of California, San Francisco and Stanford University Institutional Review Boards approved this study (#16-21213). Written informed consent was obtained from all participants.
: Not applicable.
: Dr. Obedin-Maliver has consulted for Sage Therapeutics (5/2017) in a one-day advisory board, Ibis Reproductive Health (a non-for-profit research group; 3/2017–5/2018, 2020-present), Folx, Inc. (2020—present), and Hims Inc. (2019—present). Dr. Lunn has consulted for Hims Inc. (2019—present) and Folx, Inc. (2020). Dr. Flentje has consulted for Hopelab (2020). None of these roles present a conflict of interest with this work as described here. The other authors have no conflicts of interest to report.
